已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Reply to Willoughby

医学 计算机科学
作者
Stacy Holzbauer,Caroline A. Schrodt,Rajesh M. Prabhu,Rebecca J Asch-Kendrick,Malia J Ireland,Carrie A. Klumb,Melanie J. Firestone,Gong‐Ping Liu,Katie Harry,Min Z. Levine,Lillian A. Orciari,Kimberly Wilkins,James A. Ellison,Hui Zhao,Michael Niezgoda,Panayampalli Subbian Satheshkumar,Brett W. Petersen,Agam K. Rao,W Robert Bell,Sara Forrest
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:77 (6): 931-932
标识
DOI:10.1093/cid/ciad295
摘要

We thank Willoughby for his thoughtful comments regarding rabies post-exposure prophylaxis (PEP) schedules for elderly persons [1]. Indeed, people are living longer, some with health conditions or treatments that can negatively impact vaccination response. Over the past 30 years, among an estimated 1.8 million people in the United States who received modern cell-culture rabies vaccines as part of rabies PEP, no breakthrough infections attributed to being elderly were identified [2]. While it is true that a recent systematic review that evaluated the immunogenicity after rabies vaccines [3] found that the geometric mean titer (GMT) after rabies vaccinations is lower for persons aged >60 years compared with younger persons, the median peak GMT among these persons was still substantially higher (13.2 IU/mL) than the Advisory Committee on Immunization Practices (ACIP) targeted antibody titer of 0.5 IU/mL [4]. In the absence of an immunocompromising condition, being elderly alone does not appear to be a risk factor for suboptimal immune responses after rabies vaccination. The same publication identified the GMT after intramuscular administration of rabies vaccines to be higher for longer periods of time than those after intradermal administration. Since rabies vaccines in the United States are administered intramuscularly, these data further indicate that the vaccination strategy facilitates appropriate GMTs in elderly persons. While data indicate that it takes longer (42 days vs 30 days) to reach peak levels among older persons compared with younger persons, the wide availability of rabies immune globulin in the United States is further expected to facilitate adequate protection. In addition to the currently recommended vaccination schedule likely being effective for elderly persons, the costs of titer checks for elderly persons may be a deterrent if such a broad recommendation were made. As Willoughby emphasizes, nearly 25% of people receiving PEP in the United States are likely aged >65 years. However, if all approximately 15 000 elderly PEP patients were to receive an antibody titer (estimated at $400 in medical-associated costs from a commercial laboratory), this recommendation would result in an additional $180 million in titer-related costs over 30 years. Research for alternate rabies vaccine schedules and development of future rabies vaccines for humans and animals should continue. However, at present, the current vaccines have proven efficacious. Developing a messenger RNA (mRNA) vaccine for approximately 60 000 patients per year is unlikely; this would involve multiyear clinical trials, US Food and Drug Administration approvals, and ACIP guidelines. With an estimated 30 million people getting rabies PEP globally, perhaps mRNA vaccine development holds more promise from a global approach [5]. The concern of an expanding elderly population in the United States deserves more attention. To prevent host-mediated vaccine failures, we should expand our understanding of the efficacy of vaccines in elderly populations, improve our understanding of commonly overlooked immunological disorders in this population, and provide clinician education regarding when titers are necessary. With the limited data available and the rarity of rabies vaccine failure, we reiterate our suggestion that persons with concerning rabies exposures be evaluated, regardless of age, for immunocompromise. Disclaimer. The views expressed here are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention. This work was written by (a) US Government employee(s) and is in the public domain in the United States.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
王化省发布了新的文献求助10
刚刚
ll完成签到 ,获得积分10
2秒前
konnie完成签到 ,获得积分10
3秒前
4秒前
36hours完成签到,获得积分10
7秒前
瓶子完成签到 ,获得积分10
7秒前
JamesPei的应助被隐形的晓灵采纳,获得10
9秒前
科研小秦完成签到,获得积分10
9秒前
9秒前
学术小菜鸟完成签到 ,获得积分10
10秒前
13秒前
14秒前
刻苦乐天发布了新的文献求助10
14秒前
飘逸盛男完成签到,获得积分10
16秒前
难过元灵完成签到 ,获得积分10
16秒前
19秒前
chiaoyin999发布了新的文献求助10
20秒前
fantasy的应助被二千采纳,获得10
21秒前
李爱国的应助被vc采纳,获得10
21秒前
23秒前
23秒前
乐乐的应助被丸子采纳,获得10
25秒前
25秒前
Zcl完成签到 ,获得积分10
26秒前
早八不迷路完成签到 ,获得积分10
26秒前
26秒前
超级翰完成签到 ,获得积分10
26秒前
FashionBoy的应助被luwa采纳,获得10
27秒前
十七完成签到 ,获得积分10
28秒前
哲000完成签到 ,获得积分10
28秒前
努力学习中完成签到,获得积分10
29秒前
lc发布了新的文献求助10
29秒前
xing_xing的应助被Sepnine9采纳,获得20
30秒前
qfc完成签到,获得积分10
31秒前
王图图完成签到 ,获得积分10
31秒前
英勇问晴完成签到,获得积分10
31秒前
007完成签到,获得积分10
31秒前
33秒前
SciGPT的应助被科研通管家采纳,获得10
33秒前
思源的应助被科研通管家采纳,获得10
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184889
求助须知:如何正确求助?哪些是违规求助? 9573836
关于积分的说明 21833242
捐赠科研通 7782263
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558581
邀请新用户注册赠送积分活动 2481082